Skip to the main content

Psychiatria Danubina, Vol. 33 No. broj 4, 2021.

Original scientific paper

https://doi.org/10.24869/psyd.2021.523

ADVERSE EVENTS OF ANTIPSYCHOTICS AND CYTOCHROME POLYMORPHISMS: A CASE SERIES ON 31 PATIENTS

Giuseppe Maina ; Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy ;San Luigi Gonzaga University Hospital, Turin, Italy
Stefano Bramante ; Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy ;San Luigi Gonzaga University Hospital, Turin, Ital
Antonio Borsotti ; Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy ;San Luigi Gonzaga University Hospital, Turin, Ital
Francesco Oliva ; San Luigi Gonzaga University Hospital, Turin, Italy ; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
Sylvia Rigardetto ; San Luigi Gonzaga University Hospital, Turin, Italy
Umberto Albert ; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy ; Department of Mental Health, Psychiatric Clinic, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy

Full text: english pdf 371 Kb

page 523-531

downloads: 244

cite

Abstract

Background: Adverse events (AEs) contribute to poor outcome in patients affected by mental disorders. The aim of this case
series is to describe how many antipsychotics-associated serious AEs could have been prevented if we had known in advance the
genetic profile of the patient.
Subjects and methods: Data of patients who required the prescription of an antipsychotic drug, with a history of a documented
antipsychotics-associated serious AE and who underwent Neurophar􀁐􀁄􀁊􀁈􀁑􀂊􀀃􀁗􀁈st were retrospectively collected.
Results: Thirty-three subjects were selected for eligibility; two of them were excluded. Twelve subjects (38.7%) showed genetic
polymorphisms most likely associated to an increased risk of AE, with pharmacokinetic variations being the most prevalent.
Moreover, the 35.5% of the total sample revealed drug-drug interactions (pharmacodynamic/pharmacokinetic) associated with
increased risk of AE.
Conclusions: This case series highlights how pharmacogenetics testing with decision support tools, if applied earlier during the
treatment with antipsychotics, could have led to identifying individuals at risk for serious AEs.

Keywords

adverse events; antipsychotics; neuropharmagen; pharmacogenetics; cytochromes

Hrčak ID:

269096

URI

https://hrcak.srce.hr/269096

Publication date:

21.12.2021.

Visits: 621 *